Prometheus Bio (RXDX) with a buyer of 1000 January $60/$90 call spreads on 11/9 as a Biotech showing relative strength in 2022 with shares higher by 25% YTD.
RXDX is a clinical-stage biotechnology company pioneering a precision medicine approach t...